Real-World Effectiveness and Safety of Escalating Once-Weekly Semaglutide from 0.5 to 1.0 mg in Type 2 Diabetes.

However, the key metabolic outcomes—HbA1c level, body weight, BMI, and total daily insulin dose—consistently showed highly significant improvements (nominal p < 0.01); therefore, these findings reflect a robust therapeutic signal rather than incidental findings (type I error).

also in 132,142 other papers